J&J subsidiary seeks approval for Type 2 diabetes drug

Janssen Research & Development submits application for canagliflozin-metformin combination therapy

RARITAN, N.J. — A subsidiary of Johnson & Johnson is seeking regulatory approval for a new Type 2 diabetes drug.

J&J division Janssen Research & Development announced Wednesday that it had filed with the Food and Drug Administration for a drug combining the experimental drug canagliflozin and immediate-release metformin, a common generic drug for diabetes.

The company also submitted a regulatory approval application to the FDA for canagliflozin in May 2012.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

Login or Register to post a comment.